Malignant Pleural Mesothelioma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical

Malignant Pleural Mesothelioma Pipeline constitutes 20+ key companies continuously working towards developing 20+ Malignant Pleural Mesothelioma treatment therapies, analyzes DelveInsight.

Malignant Pleural Mesothelioma Overview:

Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the pleural surface. It is commonly linked to previous asbestos exposure, with a latency period of about 40 years between exposure to the fibers and the onset of the disease. The global incidence of MPM has been steadily increasing over the past decade and is expected to reach its peak around 2020. The prognosis for MPM is poor, with median survival ranging from 8 to 14 months after diagnosis. Women tend to have a more favorable prognosis than men, but because the disease is primarily occupational, it is more common in men, with a male-to-female ratio of 4:1. There are four main histological subtypes of MPM: epithelioid, sarcomatoid, biphasic (mixed), and desmoplastic. Most cases of MPM are attributed to asbestos exposure, which often occurred more than 40 years ago. Other causes include erionite (a mineral found in Turkey), chest wall radiation, and simian virus.

Download malignant pleural mesothelioma pipeline insights report @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Malignant Pleural Mesothelioma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Pleural Mesothelioma Therapeutics Market.

Key Takeaways from the Malignant Pleural Mesothelioma Pipeline Report

DelveInsight's Malignant Pleural Mesothelioma pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Malignant Pleural Mesothelioma treatment.
In September 2024, The FDA has approved Merck's KEYTRUDA® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Key Malignant Pleural Mesothelioma companies such as MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Novartis, Bristol-Myers Squibb, Novartis, TCR2 Therapeutics, Novotech (Australia) Pty Limited, AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others are evaluating new drugs for Malignant Pleural Mesothelioma to improve the treatment landscape.
Promising Malignant Pleural Mesothelioma pipeline therapies in various stages of development include Semaglutide, ACP 01, Revacept, and others.

Malignant Pleural Mesothelioma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Malignant Pleural Mesothelioma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Malignant Pleural Mesothelioma market.

Request for a detailed informative report on malignant plural mesothelioma pipeline insights @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Malignant Pleural Mesothelioma Emerging Drugs

NGR-TNF: MolMed
Pembrolizumab : Merck & Co
Pegargiminase: Polaris Pharmaceuticals
Lurbinectedin: PharmaMar
YS110: Ys Therapeutics

Malignant Pleural Mesothelioma Companies

Over 20 major companies are working on developing therapies for Malignant Pleural Mesothelioma. Among them, MolMed has drug candidates for the condition in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Malignant Pleural Mesothelioma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Malignant Pleural Mesothelioma Therapies and Key Companies: Malignant Pleural Mesothelioma Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment
• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type

Download Malignant Pleural Mesothelioma Sample report to know in detail about the Malignant Pleural Mesothelioma treatment market @ Malignant Pleural Mesothelioma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Malignant Pleural Mesothelioma Current Treatment Patterns
4. Malignant Pleural Mesothelioma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Malignant Pleural Mesothelioma Late-Stage Products (Phase-III)
7. Malignant Pleural Mesothelioma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Malignant Pleural Mesothelioma Discontinued Products
13. Malignant Pleural Mesothelioma Product Profiles
14. Malignant Pleural Mesothelioma Key Companies
15. Malignant Pleural Mesothelioma Key Products
16. Dormant and Discontinued Products
17. Malignant Pleural Mesothelioma Unmet Needs
18. Malignant Pleural Mesothelioma Future Perspectives
19. Malignant Pleural Mesothelioma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Malignant Pleural Mesothelioma Pipeline Reports Offerings: @https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

This release was published on openPR.